Matthew I. Milowsky

18.0k total citations · 7 hit papers
274 papers, 10.2k citations indexed

About

Matthew I. Milowsky is a scholar working on Surgery, Pulmonary and Respiratory Medicine and Oncology. According to data from OpenAlex, Matthew I. Milowsky has authored 274 papers receiving a total of 10.2k indexed citations (citations by other indexed papers that have themselves been cited), including 200 papers in Surgery, 104 papers in Pulmonary and Respiratory Medicine and 100 papers in Oncology. Recurrent topics in Matthew I. Milowsky's work include Bladder and Urothelial Cancer Treatments (186 papers), Urinary and Genital Oncology Studies (112 papers) and Cancer Immunotherapy and Biomarkers (52 papers). Matthew I. Milowsky is often cited by papers focused on Bladder and Urothelial Cancer Treatments (186 papers), Urinary and Genital Oncology Studies (112 papers) and Cancer Immunotherapy and Biomarkers (52 papers). Matthew I. Milowsky collaborates with scholars based in United States, Canada and Italy. Matthew I. Milowsky's co-authors include David M. Nanus, Neil H. Bander, Stanley J. Goldsmith, Dean F. Bajorin, Shankar Vallabhajosula, Lale Kostakoğlu, William Y. Kim, Gopa Iyer, Sara E. Wobker and Matthew E. Nielsen and has published in prestigious journals such as Science, Proceedings of the National Academy of Sciences and Journal of Clinical Investigation.

In The Last Decade

Matthew I. Milowsky

258 papers receiving 10.1k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Intrinsic subtypes of high-grade bladder cancer reflect the hallmarks of breast cancer biology

2014 613 citations Jeffrey S. Damrauer, Katherine A. Hoadley et al. profile →
Genome Sequencing Identifies a Basis for Everolimus Sensitivity

2012 480 citations Gopa Iyer, Aphrothiti J. Hanrahan et al. Science profile →
A Systematic Review of Strategies to Prevent Cisplatin-Induced Nephrotoxicity

2017 288 citations Matthew D. Galsky, Matthew I. Milowsky et al. profile →
EV-101: A Phase I Study of Single-Agent Enfortumab Vedotin in Patients With Nectin-4–Positive Solid Tumors, Including Metastatic Urothelial Carcinoma

2020 223 citations Jonathan E. Rosenberg, Srikala S. Sridhar et al. Journal of Clinical Oncology profile →
The 2021 Updated European Association of Urology Guidelines on Metastatic Urothelial Carcinoma

2021 212 citations Matthew I. Milowsky et al. European Urology profile →
Management of Metastatic Clear Cell Renal Cell Carcinoma: ASCO Guideline

2022 175 citations Hikmat Al‐Ahmadie, Hamid Emamekhoo et al. Journal of Clinical Oncology profile →
Enfortumab Vedotin Plus Pembrolizumab in Previously Untreated Advanced Urothelial Cancer

2022 163 citations Christopher Hoimes, Thomas W. Flaig et al. Journal of Clinical Oncology profile →

Peers

Countries citing papers authored by Matthew I. Milowsky

Since Specialization

Citations

This map shows the geographic impact of Matthew I. Milowsky's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Matthew I. Milowsky with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Matthew I. Milowsky more than expected).

Fields of papers citing papers by Matthew I. Milowsky

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Matthew I. Milowsky. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Matthew I. Milowsky. The network helps show where Matthew I. Milowsky may publish in the future.

Co-authorship network of co-authors of Matthew I. Milowsky

This figure shows the co-authorship network connecting the top 25 collaborators of Matthew I. Milowsky. A scholar is included among the top collaborators of Matthew I. Milowsky based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Matthew I. Milowsky. Matthew I. Milowsky is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Adjuvant nivolumab in muscle-invasive urothelial carcinoma: exploratory biomarker analysis of the randomized phase 3 CheckMate 274 trial 2025 ·Nature Medicine ·Matthew D. Galsky, Dean F. Bajorin, Yoshihiko Tomita, Dingwei Ye, Mads Agerbæk, Deborah Enting, Avivit Peer, Matthew I. Milowsky, Ko Kobayashi, Marc‐Oliver Grimm, Frank Stenner, Justin M. David, (unknown), Scott D. Chasalow, Federico Nasroulah, (unknown), Keziban Ünsal-Kaçmaz, Andrea Necchi	0
2	3077P Enfortumab vedotin with pembrolizumab (EVP) treatment outcomes in patients with histologic subtypes of advanced urothelial carcinoma: Analysis of the UNITE study 2025 ·Annals of Oncology ·(unknown), C.-Y. Jiang, Omar Alhalabi, Edwin C. Oh, An‐Soo Jang, (unknown), Hamid Emamekhoo, Christopher Hoimes, Mehmet Asım Bilen, Yousef Zakharia, Shilpa Gupta, Matthew I. Milowsky, (unknown), (unknown), Archana Tripathi, (unknown), Jennifer R. Brown, (unknown), Matthew T. Campbell, (unknown)	0
3	Evorpacept plus enfortumab vedotin in patients (Pts) with locally advanced or metastatic urothelial carcinoma (la/mUC): Phase 1a dose escalation results. 2024 ·Journal of Clinical Oncology ·Samuel A. Funt, Petros Grivas, Xīn Gào, Daniel A. Vaena, Tian Zhang, Matthew I. Milowsky, (unknown), Harry Liu, Kimberly Tipton, (unknown), Feng Jin, Alison Forgie, Sophia Randolph, Athanasios C. Tsiatis, (unknown)	1
4	The Binding Site Barrier Elicited by Tumor-Associated Fibroblasts Interferes Disposition of Nanoparticles in Stroma-Vessel Type Tumors 2024 ·UNC Libraries ·(unknown), Lu Zhang, Matthew I. Milowsky, Feifei Xu, Jay Newby, William Y. Kim, C. Michael Lin, M. Gregory Forest, Sara E. Wobker, Samuel K. Lai, Leaf Huang	0
5	Poor Prognosis among Radiation-Associated Bladder Cancer Is Defined by Clinicogenomic Features 2024 ·Cancer Research Communications ·N. Ari Wijetunga, (unknown), Krishna Kanchi, Jay A. Moore, (unknown), Dexter X. Jin, Garrett M. Frampton, (unknown), Michael Repka, (unknown), David L. Corcoran, Matthew D. Galsky, Matthew I. Milowsky, Sara E. Wobker, William Y. Kim, Tracy L. Rose, Jeffrey S. Damrauer	3
6	Clinical Implications of Basic Research: Exploring the Transformative Potential of Spatial 'Omics in Uro-oncology 2024 ·European Urology ·(unknown), Anthony S. Bates, David A. Braun, Renu Eapen, Markus Eckstein, Brandon J. Manley, Matthew I. Milowsky, Thomas J. Mitchell, Richard J. Bryant, John P. Sfakianos, Alastair Lamb	5
7	Spatial Relationships in the Tumor Microenvironment Demonstrate Association with Pathologic Response to Neoadjuvant Chemoimmunotherapy in Muscle-invasive Bladder Cancer 2023 ·European Urology ·(unknown), Sara E. Wobker, Jeffrey S. Damrauer, Bentley R. Midkiff, Gabriela De la Cruz, (unknown), Leah M. Flick, Mark G. Woodcock, Petros Grivas, Marc A. Bjurlin, Michael R. Harrison, Benjamin G. Vincent, Tracy L. Rose, Shilpa Gupta, William Y. Kim, Matthew I. Milowsky	11
8	A Plain Language Summary Exploring a New Treatment Combination for Untreated Locally Advanced or Metastatic Urothelial Cancer: Enfortumab Vedotin Plus Pembrolizumab 2023 ·Future Oncology ·Christopher Hoimes, Thomas W. Flaig, Matthew I. Milowsky, Terence W. Friedlander, Mehmet Asım Bilen, Shilpa Gupta, Sandy Srinivas, Jaime R. Merchan, Rana R. McKay, Daniel P. Petrylak, Carolyn Sasse, Blanca Homet Moreno, Yao Yu, Anne‐Sophie Carret, Jonathan E. Rosenberg	3
9	Feasibility of home-based exercise training in men with metastatic castration-resistant prostate cancer 2022 ·Prostate Cancer and Prostatic Diseases ·Erik D. Hanson, (unknown), (unknown), (unknown), Alexander R. Lucas, Young E. Whang, Matthew I. Milowsky, David B. Bartlett, Michael R. Harrison, Rhonda L. Bitting, Allison M. Deal, Lee Stoner, Anthony C. Hackney, Cláudio L. Battaglini	11
10	Collaborative study from the Bladder Cancer Advocacy Network for the genomic analysis of metastatic urothelial cancer 2022 ·Nature Communications ·Jeffrey S. Damrauer, (unknown), Jeffrey A. Klomp, Mi Zhou, Elizabeth R. Plimack, Matthew D. Galsky, Petros Grivas, Noah M. Hahn, Peter H. O’Donnell, Gopa Iyer, David I. Quinn, Benjamin G. Vincent, Diane Zipursky Quale, Sara E. Wobker, Katherine A. Hoadley, William Y. Kim, Matthew I. Milowsky	27
11	Enfortumab Vedotin Plus Pembrolizumab in Previously Untreated Advanced Urothelial Cancer breakdown → 2022 ·Journal of Clinical Oncology ·Christopher Hoimes, Thomas W. Flaig, Matthew I. Milowsky, Terence W. Friedlander, Mehmet Asım Bilen, Shilpa Gupta, Sandy Srinivas, Jaime R. Merchan, Rana R. McKay, Daniel P. Petrylak, Carolyn Sasse, Blanca Homet Moreno, Yao Yu, Anne‐Sophie Carret, Jonathan E. Rosenberg	163
12	A Randomized Phase II Study of Coexpression Extrapolation (COXEN) with Neoadjuvant Chemotherapy for Bladder Cancer (SWOG S1314; NCT02177695) 2021 ·Clinical Cancer Research ·Thomas W. Flaig, Catherine M. Tangen, Siamak Daneshmand, Ajjai Alva, Seth P. Lerner, M. Scott Lucia, David J. McConkey, Dan Theodorescu, Amir Goldkorn, Matthew I. Milowsky, Rick Bangs, Gary R. MacVicar, Bruno R. Bastos, Jared S. Fowles, Daniel L. Gustafson, Melissa Plets, Ian M. Thompson	58
13	Identification of a Novel Inflamed Tumor Microenvironment Signature as a Predictive Biomarker of Bacillus Calmette-Guérin Immunotherapy in Non–Muscle-Invasive Bladder Cancer 2021 ·Clinical Cancer Research ·Jeffrey S. Damrauer, Kyle R. Roell, (unknown), Xuezheng Sun, Erin L. Kirk, Katherine A. Hoadley, Halei C. Benefield, Gopa Iyer, David B. Solit, Matthew I. Milowsky, William Y. Kim, Matthew E. Nielsen, Sara E. Wobker, Guido Dalbagni, Hikmat Al‐Ahmadie, Andrew F. Olshan, Bernard H. Bochner, Helena Furberg, Melissa A. Troester, Eugene J. Pietzak	33
14	A phase 2 trial of buparlisib in patients with platinum‐resistant metastatic urothelial carcinoma 2020 ·Cancer ·Victor McPherson, Brendan Reardon, (unknown), Sasinya N. Scott, Mariel Elena Boyd, Ilana Garcia-Grossman, Ashley Marie Regazzi, Asia S. McCoy, Philip H. Kim, Hikmat Al‐Ahmadie, Irina Ostrovnaya, Andrew Roth, Azeez Farooki, Michael F. Berger, Jonathan E. Rosenberg, David B. Solit, Eliezer M. Van Allen, Matthew I. Milowsky, Dean F. Bajorin, Gopa Iyer	20
15	Secondary Immune Thrombocytopenia in Metastatic Renal Cell Carcinoma: A Case Report and Discussion of the Literature 2020 ·Case Reports in Oncology ·(unknown), Raj S. Kasthuri, Ersan Altun, Tracy L. Rose, Matthew I. Milowsky	3
16	EV-101: A Phase I Study of Single-Agent Enfortumab Vedotin in Patients With Nectin-4–Positive Solid Tumors, Including Metastatic Urothelial Carcinoma breakdown → 2020 ·Journal of Clinical Oncology ·Jonathan E. Rosenberg, Srikala S. Sridhar, Jingsong Zhang, David C. Smith, Dean Ruether, Thomas W. Flaig, Joaquina Baranda, Joshua M. Lang, Elizabeth R. Plimack, Randeep Sangha, Elisabeth I. Heath, (unknown), David I. Quinn, Sandy Srinivas, Matthew I. Milowsky, Chunzhang Wu, Elaina M. Gartner, Peiying Zuo, Amal Melhem‐Bertrandt, Daniel P. Petrylak	223
17	Phase II Study of Lutetium-177–Labeled Anti-Prostate-Specific Membrane Antigen Monoclonal Antibody J591 for Metastatic Castration-Resistant Prostate Cancer 2013 ·Clinical Cancer Research ·Scott T. Tagawa, Matthew I. Milowsky, Michael J. Morris, Shankar Vallabhajosula, Paul J. Christos, Naveed Akhtar, Joseph R. Osborne, Stanley J. Goldsmith, Steven M. Larson, Neeta Pandit Taskar, Howard I. Scher, Neil H. Bander, David M. Nanus	308
18	Genome Sequencing Identifies a Basis for Everolimus Sensitivity breakdown → 2012 ·Science ·Gopa Iyer, Aphrothiti J. Hanrahan, Matthew I. Milowsky, Hikmat Al‐Ahmadie, Sasinya N. Scott, Manickam Janakiraman, Mono Pirun, Chris Sander, Nicholas D. Socci, Irina Ostrovnaya, Agnès Viale, Adriana Heguy, (unknown), Timothy A. Chan, Bernard H. Bochner, Dean F. Bajorin, Michael F. Berger, Barry S. Taylor, David B. Solit	480
19	Phase I trial of interferon α2b and liposome‐encapsulated all‐trans retinoic acid in the treatment of patients with advanced renal cell carcinoma 2002 ·Cancer ·Jonathan S. Goldberg, (unknown), (unknown), Matthew I. Milowsky, (unknown), Lorraine J. Gudas, Gary Shelton, Kevie Feit, Daniel P. Petrylak, David M. Nanus	19
20	Active chemotherapy for collecting duct carcinoma of the kidney 2001 ·Cancer ·Matthew I. Milowsky, (unknown), Satish K. Tickoo, Nicholas Papanicolaou, David M. Nanus	69

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact